| Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology U Prabhakar, H Maeda, RK Jain, EM Sevick-Muraca, W Zamboni, ... Cancer research 73 (8), 2412-2417, 2013 | 1560 | 2013 |
| Using mechanobiological mimicry of red blood cells to extend circulation times of hydrogel microparticles TJ Merkel, SW Jones, KP Herlihy, FR Kersey, AR Shields, M Napier, ... Proceedings of the National Academy of Sciences 108 (2), 586-591, 2011 | 611 | 2011 |
| Liposomal, nanoparticle, and conjugated formulations of anticancer agents WC Zamboni Clinical cancer research 11 (23), 8230-8234, 2005 | 305 | 2005 |
| Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy PJ Roberts, JE Bisi, JC Strum, AJ Combest, DB Darr, JE Usary, ... Journal of the National Cancer Institute 104 (6), 476-487, 2012 | 303 | 2012 |
| Best practices in cancer nanotechnology: perspective from NCI nanotechnology alliance WC Zamboni, V Torchilin, AK Patri, J Hrkach, S Stern, R Lee, A Nel, ... Clinical cancer research 18 (12), 3229-3241, 2012 | 301 | 2012 |
| Evading immune cell uptake and clearance requires PEG grafting at densities substantially exceeding the minimum for brush conformation Q Yang, SW Jones, CL Parker, WC Zamboni, JE Bear, SK Lai Molecular pharmaceutics 11 (4), 1250-1258, 2014 | 283 | 2014 |
| Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children WL Furman, CF Stewart, CA Poquette, CB Pratt, VM Santana, ... Journal of Clinical Oncology 17 (6), 1815-1815, 1999 | 274 | 1999 |
| Structure and inhibition of microbiome β-glucuronidases essential to the alleviation of cancer drug toxicity BD Wallace, AB Roberts, RM Pollet, JD Ingle, KA Biernat, SJ Pellock, ... Chemistry & biology 22 (9), 1238-1249, 2015 | 249 | 2015 |
| Mediating passive tumor accumulation through particle size, tumor type, and location JL Perry, KG Reuter, JC Luft, CV Pecot, W Zamboni, JM DeSimone Nano letters 17 (5), 2879-2886, 2017 | 225 | 2017 |
| Concept and clinical evaluation of carrier-mediated anticancer agents WC Zamboni The oncologist 13 (3), 248-260, 2008 | 219 | 2008 |
| Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model … WC Zamboni, AC Gervais, MJ Egorin, JHM Schellens, EG Zuhowski, ... Cancer chemotherapy and pharmacology 53 (4), 329-336, 2004 | 207 | 2004 |
| Plasma, tumor and tissue pharmacokinetics of Docetaxel delivered via nanoparticles of different sizes and shapes in mice bearing SKOV-3 human ovarian carcinoma xenograft KS Chu, W Hasan, S Rawal, MD Walsh, EM Enlow, JC Luft, AS Bridges, ... Nanomedicine: Nanotechnology, Biology and Medicine 9 (5), 686-693, 2013 | 174 | 2013 |
| Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models PJ Roberts, JE Usary, DB Darr, PM Dillon, AD Pfefferle, MC Whittle, ... Clinical cancer research 18 (19), 5290-5303, 2012 | 167 | 2012 |
| Low Overexpression of HER-2/Neu in Advanced Colorectal Cancer Limits the Usefulness of Trastuzumab (Herceptin®) and Irinotecan as Therapy. A Phase II Trial RK Ramanathan, JJ Hwang, WC Zamboni, FA Sinicrope, H Safran, ... Cancer investigation 22 (6), 858-865, 2004 | 167 | 2004 |
| Sensitive liquid chromatography–mass spectrometry assay for quantitation of docetaxel and paclitaxel in human plasma RA Parise, RK Ramanathan, WC Zamboni, MJ Egorin Journal of Chromatography B 783 (1), 231-236, 2003 | 152 | 2003 |
| Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts WC Zamboni, CF Stewart, PJ Houghton, J Thompson, VM Santana, ... JNCI: Journal of the National Cancer Institute 90 (7), 505-511, 1998 | 149 | 1998 |
| Efficacy of systemic administration of irinotecan against neuroblastoma xenografts. J Thompson, WC Zamboni, PJ Cheshire, L Lutz, X Luo, Y Li, JA Houghton, ... Clinical cancer research 3 (3), 423-431, 1997 | 143 | 1997 |
| Nanoparticle drug loading as a design parameter to improve docetaxel pharmacokinetics and efficacy KS Chu, AN Schorzman, MC Finniss, CJ Bowerman, L Peng, JC Luft, ... Biomaterials 34 (33), 8424-8429, 2013 | 139 | 2013 |
| Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a pediatric oncology group … DG Tubergen, CF Stewart, CB Pratt, WC Zamboni, N Winick, VM Santana, ... Journal of pediatric hematology/oncology 18 (4), 352-361, 1996 | 136 | 1996 |
| The effect of particle size on the biodistribution of low-modulus hydrogel PRINT particles TJ Merkel, K Chen, SW Jones, AA Pandya, S Tian, ME Napier, ... Journal of controlled release 162 (1), 37-44, 2012 | 123 | 2012 |
